Code intelligence

FDA-NDA214012 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA214012.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated

Critical

High

100%

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: LEQVIO (INCLISIRAN) — Type 1 - New Molecular Entity

Policy FDA-NDA214012 · Cardiology

High

Leqvio (inclisiran) is a subcutaneously administered siRNA therapy approved for LDL-C reduction, with a confirmed Part B billing pathway reflecting its physician-office or clinic administration model.

View alert

Audit documentation

Building an audit file that includes FDA-NDA214012?

The Tripwire Audit Pack exports 12 months of Cardiology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Cardiology audit pack — $349One-time purchase · not a subscription